EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers

Nicolò Bisi, Luca Pinzi iD, Giulio Rastelli iD, Nicolò Tonali iD

Molecules · 2024

DOI: 10.3390/molecules29030722 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2024. Verfasst von Nicolò Bisi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, CNRS, BioCIS, Bat. Henri Moissan, 17, Av. des Sciences, 91400 Orsay, France. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Parkinson Disease, Alzheimer Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, European Union, FAR-Fondo di Ateneo per la Ricerca 2019.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) represent two among the most frequent neurodegenerative diseases worldwide. A common hallmark of these pathologies is the misfolding and consequent aggregation of amyloid proteins into soluble oligomers and insoluble β-sheet-rich fibrils, which ultimately lead to neurotoxicity and cell death. After a hundred years of research on the subject, this is the only reliable histopathological feature in our hands. Since AD and PD are diagnosed only once neuronal death and the first symptoms have appeared, the early detection of these diseases is currently impossible. At present, there is no effective drug available, and patients are left with symptomatic and inconclusive therapies. Several reasons could be associated with the lack of effective therapeutic treatments. One of the most important factors is the lack of selective probes capable of detecting, as early as possible, the most toxic amyloid species involved in the onset of these pathologies. In this regard, chemical probes able to detect and distinguish among different amyloid aggregates are urgently needed. In this article, we will review and put into perspective results from ex vivo and in vivo studies performed on compounds specifically interacting with such early species. Following a general overview on the three different amyloid proteins leading to insoluble β-sheet-rich amyloid deposits (amyloid β1–42 peptide, Tau, and α-synuclein), a list of the advantages and disadvantages of the approaches employed to date is discussed, with particular attention paid to the translation of fluorescence imaging into clinical applications. Furthermore, we also discuss how the progress achieved in detecting the amyloids of one neurodegenerative disease could be leveraged for research into another amyloidosis. As evidenced by a critical analysis of the state of the art, substantial work still needs to be conducted. Indeed, the early diagnosis of neurodegenerative diseases is a priority, and we believe that this review could be a useful tool for better investigating this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurodegenerative DiseasesParkinson DiseaseAlzheimer DiseaseHumansAmyloid beta-PeptidesFluorescenceAmyloidAmyloidogenic ProteinsEarly DiagnosisPositron-Emission Tomography

Stichwörter der Autor:innen

Alzheimer’s diseaseAβ1–42Parkinson’s diseaseTauneurodegenerationprobestauopathiesα-synuclein

Substanzen

Amyloid beta-PeptidesAmyloidAmyloidogenic Proteins

Autor:innen und Institutionen

  • Université Paris-Saclay, CNRS, BioCIS, Bat. Henri Moissan, 17, Av. des Sciences, 91400 Orsay, France.
  • Department of Life Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi 103, 41125 Modena, Italy.

ORCID-Profile: Luca Pinzi, Giulio Rastelli, Nicolò Tonali

Förderung

  • Agence Nationale de la Recherche
  • European Union
  • FAR-Fondo di Ateneo per la Ricerca 2019
  • Fondo Sociale Europeo REACT-EU-PON
  • FAR—Fondo di Ateneo per la Ricerca 2019
  • Banca Popolare dell’Emilia-Romagna (BPER)
  • Italian funding program Fondo Sociale Europeo REACT-EU—PON
  • PRCI DFG-ANR funding program

Zitieren

APA

Bisi, N., Pinzi, L., Rastelli, G., & Tonali, N. (2024). Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers. Molecules. https://doi.org/10.3390/molecules29030722

Vancouver

Bisi N, Pinzi L, Rastelli G, Tonali N. Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers. Molecules. 2024. doi:10.3390/molecules29030722

BibTeX
@article{Bisi2024,
  author = {Bisi, Nicolò and Pinzi, Luca and Rastelli, Giulio and Tonali, Nicolò},
  title = {Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29030722}
}
Kostenlos starten →